Regorafenib monohydrate

SKU: orb1307433

Description

Regorafenib monohydrate

Research Area

Cardiovascular Research, Cell Biology, Signal Transduction

Key Properties

• CAS Number: 1019206-88-2
• MW: 500.83
• Purity: 99.69%
• Formula: C₂₁H₁₇ClF₄N₄O₄
• SMILES: O.CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1
• Target: FGFR,Autophagy,c-Kit,c-RET,Raf,PDGFR,Tie-2,VEGFR
• Solubility: DMSO:20 mg/mL (39.93 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.99 mM)

Bioactivity

• Target IC50:
  c-Kit:7 nM|Raf-1:2.5 nM|PDGFRβ:22 nM|B-Raf:28 nM|Tie2:311 ± 46 nM|VEGFR1:13 nM|VEGFR2:4.2 nM|VEGFR3:46 nM|RET:1.5 nM|B-Raf (V600E):19 nM
• In Vivo:
  Treating tumor-bearing rats with a single oral dose of regorafenib at 10 mg/kg caused a significant decrease in tumor perfusion and extravasation of the contrast agent. A significant reduction of the normalized IAUC360 was observed by 10 hr after regorafenib treatment and persisted for up to 2 days when compared with vehicle. Regorafenib dosed qd orally inhibited tumor growth in a dose-dependent manner in multiple xenograft models, including models derived from CRC (Colo-205), BC (MDA-MB-231) and RCC (786-O) tumors. Regorafenib (10–100 mg/kg) effectively inhibited the growth of the Colo-205 xenografts, reaching a TGI of ~75% at day 14 at the 10 mg/kg dose . In murine xenograft models, oral regorafenib, M-2, and M-5 significantly inhibited tumor growth versus controls. Total peak plasma drug concentrations and exposure to M-2 and M-5 in mice after repeated oral dosing with regorafenib 10 mg/kg/day were comparable to those in humans .
• In Vitro:
  Regorafenib potently inhibited a distinct set of kinases, including the angiogenic and stromal RTKs VEGFR1-3, TIE2, FGFR1 and PDGFR-b (IC50s: 4-311 nM), and the oncogenic RTKs KIT and RET, along with the intracellular signaling kinases c-RAF/RAF-1 and BRAF and its V600E mutant (IC50s: 1.5-28 nM). Regorafenib potently inhibited VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells (IC50: 3 nM). In HAoSMCs, regorafenib inhibited PDGFR-b autophosphorylation after stimulation with PDGF-BB (IC50: 90 nM) . Regorafenib caused a concentration-dependent decrease in Hep3B cell growth (IC50: 5 μM). PLC/PRF/5 cells were similar in their responses to Hep3B cells, but HepG2 cells were more sensitive (IC50: 1 μM) .
• Cell Research:
  Each cell line was seeded at 0.3×10^5 cells/2ml of DMEM containing 10% FBS in 35 mm tissue culture dishes. The cells were incubated for 24 h to allow attachment, and then the medium was replaced by fresh culture medium containing Regorafenib at increasing concentrations (1 μM, 2.5 μM, 5 μM, 7.5 μM and 10 μM). In these experimental conditions, the cells were allowed to grow for 72 or 96 h.Time-course experiments on Hep3B cells were performed with 7.5 μM of Regorafenib at short (15, 60, 180 min.), middle (24, 48, 72 and 96 h) or long times (up to seven days). When the cells were treated for long times the drug was replaced with a fresh one. Each experiment included a control with the equivalent concentration of DMSO (solvent control) as the one used for adding Regorafenib. Each experiment was performed in triplicate and repeated 3 times. Subsequent analyses were performed at specific Regorafenib concentrations and incubation times .
• Animal Research:
  Female athymic NCr nu/nu mice, kept in accordance with Federal guidelines, were subcutaneously inoculated with 5×10^6 Colo-205 or MDAMB-231 cells or implanted with 1 mm^3 786-O tumor fragments. When tumors reached a volume of ~100 mm^3, regorafenib or vehicle control was administered orally qd×21 in the 786-O model, and qd×9 in the Colo-205 and MDA-MB231 models, respectively, at doses of 100, 30, 10, and 3 mg/kg. Paclitaxel was administered intravenously at 10 mg/kg in ethanol/Cremophor ELV/saline (12.5%/12.5%/75%) every 2 days×5. Tumor size (volume) was estimated twice weekly (l×w^2)/2, and the percentage of tumor growth inhibition (TGI) was obtained from terminal tumor weights (1-T/C100). Mice were weighed every other day starting from the first day of treatment. The general health status of the mice was monitored daily .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RET, PDGFRβ, PDGFR, Regorafenib, Regorafenib monohydrate, Regorafenib Monohydrate, RAF-1, Raf kinases, Raf, tumor, VEGFR, Vascular endothelial growth factor receptor, Colo-205, cKit, cRET, BAY 73-4506, B-RAF, B-Raf (V600E), antiangiogenic, Antitumorigenic, Autophagy, 786-O, Inhibitor, HUVECs, Hep3B cell, HAoSMCs, inhibit, Kit, murine VEGFR2, murine VEGFR3, Platelet-derived growth factor receptor, NIH-3T3

Compound Identifiers

PubChem CID

24768591